Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 271 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Methylphenidate Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Neural Correlates of Acute Pain Dynamics

NCT05669924
View directory record Official record
Conditions
Pain
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 1, 2026, 10:41 AM EDT
Completed Phase 1 Interventional

Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate

NCT02361125
View directory record Official record
Conditions
Fatigue
Interventions
Methylphenidate, Fatigue Evaluations
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Sep 1, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis

NCT03185065
View directory record Official record
Conditions
Fatigue in Multiple Sclerosis
Interventions
Amantadine, Modafinil, Methylphenidate, Placebos
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 1, 2026, 10:41 AM EDT
Completed Phase 1 Interventional

Cocaine-Methylphendidate Interaction Study - 4

NCT00015067
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 1, 2026, 10:41 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Behavioral Effects of Drugs: Inpatient (35)

NCT03519022
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Cocaine, Placebo oral capsule, Methylphenidate
Drug
Lead sponsor
Craig Rush
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 1, 2026, 10:41 AM EDT
Not listed Phase 4 Interventional

Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

NCT03781765
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Atomoxetine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 1, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects

NCT00302367
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OROS methylphenidate hydrochloride, immediate release methylphenidate hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 1, 2026, 10:41 AM EDT
Recruiting Phase 1 Interventional

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

NCT07559500
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Tirzepatide, Placebo, [11C]raclopride plus drug, [11C]NNC-112
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 1, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00409708
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy, Behavior Therapy
Drug · Behavioral
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2011 · Synced Sep 1, 2026, 10:41 AM EDT
Terminated Not applicable Interventional Results available

Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

NCT01100658
View directory record Official record
Conditions
ALL, Childhood, Leukemia, Lymphoblastic, Leukemia, Lymphoblastic, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Acute, L1, Leukemia, Lymphocytic, Acute, L2, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute, L1, Lymphoblastic Leukemia, Acute, L2, Lymphoblastic Lymphoma, Lymphocytic Leukemia, Acute, Lymphocytic Leukemia, L1, Lymphocytic Leukemia, L2, Brain Tumors, Cancer of the Brain, Cancer of Brain, Malignant Primary Brain Tumors, Brain Neoplasms, Malignant
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
8 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Sep 1, 2026, 10:41 AM EDT
Withdrawn Phase 4 Interventional

Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate

NCT00931398
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
methylphenidate HCl (Concerta), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Sep 1, 2026, 10:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding Sleep Problems in Children With Autism Spectrum Disorder

NCT00691080
View directory record Official record
Conditions
Sleep Problems
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
4 Years to 9 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
3
States / cities
New York, New York • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Sep 1, 2026, 10:41 AM EDT
Completed Phase 3 Interventional

Methylphenidate in Treating Patients With Melanoma

NCT00003266
View directory record Official record
Conditions
Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
methylphenidate hydrochloride, quality-of-life assessment
Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
57
States / cities
Scottsdale, Arizona • Palo Alto, California • Stanford, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 1, 2026, 10:41 AM EDT
Completed No phase listed Observational

IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

NCT01232361
View directory record Official record
Conditions
ADHD, HIV
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 25 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 1, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Results available

Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD

NCT02096952
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder
Interventions
Methylphenidate extended-release liquid formulation
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 1, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00253747
View directory record Official record
Conditions
ADHD, Smoking
Interventions
Osmotic-Release Methylphenidate, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
6
States / cities
Cambridge, Massachusetts • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2012 · Synced Sep 1, 2026, 10:41 AM EDT
Terminated Phase 2 Interventional

Cognitive REmediation After Trauma Exposure Trial = CREATE Trial

NCT01416948
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Methylphenidate Hydrochloride 20 mg, Placebo Capsule, Galantamine 12 mg
Drug
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
San Diego, California • Boston, Massachusetts • Manchester, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Sep 1, 2026, 10:41 AM EDT
Terminated No phase listed Observational

Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics

NCT00247689
View directory record Official record
Conditions
Substance Abuse
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 1, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Methylphenidate Treatment of Attention Deficits in Epilepsy

NCT02178995
View directory record Official record
Conditions
Epilepsy, Cognitive Deficits, Attention Deficits
Interventions
Methylphenidate
Drug
Lead sponsor
Kimford Jay Meador
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 1, 2026, 10:41 AM EDT
Completed Early Phase 1 Interventional

Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD

NCT02874690
View directory record Official record
Conditions
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Sep 1, 2026, 10:41 AM EDT
Terminated Phase 4 Interventional Results available

Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT04507204
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Adhansia XR, Concerta
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
12 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
35
States / cities
Dothan, Alabama • Beverly Hills, California • Cromwell, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 1, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01835548
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
NT0102, Placebo
Drug
Lead sponsor
Neos Therapeutics, Inc
Industry
Eligibility
6 Years to 12 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 1, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Results available

Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children

NCT00754208
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
methylphenidate
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
4 Years to 5 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 1, 2026, 10:41 AM EDT
Completed Not applicable Interventional Results available

Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD

NCT00989950
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, INSOMNIA
Interventions
Daytrana
Drug
Lead sponsor
Cox Health Systems
Other
Eligibility
6 Years to 12 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Sep 1, 2026, 10:41 AM EDT